ClinicalTrials.gg
TerminatedNCT03172936Updated May 3, 2022

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

A Phase 1 interventional study of MIW815 and PDR001 in Solid Tumors and Lymphomas, sponsored by Novartis Pharmaceuticals. Terminated at 12 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor's decision

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Lymphoma by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Lymphoma · Novartis.

Enrollment
6th of 19
106 · median 60
Started
2017
with 1 other
Phase 1
11 of 20
none open now
Registered
15th of 20
by date

Among the 20 studies in Lymphoma by Novartis, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2017, is one of 11 in phase 1, and was the 15th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 20 studies in Lymphoma by Novartis is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lymphoma by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.

Read the detailed description

This was a Phase Ib, multi-center, open-label study to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of MIW815(ADU-S100) in combination with the PD-1 checkpoint inhibitor PDR001. Two different schedules were explored in two dose escalation groups in accessible cutaneous or subcutaneous lesions. The optional dose confirmation group exploring intratumoral injection of viscerally located lesions was not opened due to the program's early termination.

Group A included patients with accessible solid tumors and lymphomas. This group received a fixed dose of PDR001 i.v. on day 1 of every 28 day cycle and intratumoral injections of MIW815 (ADU-S100) on days 1, 8 and 15 of every 28 day cycle. Group B included patients with accessible solid tumors and lymphomas. This group received a fixed dose of PDR001 i.v. on day 1 of every 28 day cycle and an intratumoral injection of MIW815 (ADU-S100) on day 1 of every 28 day cycle.

Once the dose and dose schedule had been confirmed, the plan was to open the dose expansion part of the study. However, the expansion phase of the study was not opened to enrollment due to the program's early termination.

03

Conditions studied

  • Solid Tumors and Lymphomas

Browse trials for

Keywords

  • injected lesion
  • distal lesion
  • abscopal activity
  • intratumoral
  • checkpoint inhibitor
  • cyclic dinucleotide
  • programmed cell death
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

≤ 1 Willing to undergo tumor from injected and distal lesions

Must have two biopsy accessible lesions:

Exclusion criteria

Exclusion Criteria:

Symptomatic or untreated . Presence of symptomatic central nervous system Impaired cardiac function or cardiac disease Active disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.

Active infection requiring systemic antibiotic therapy. Known history of infection. Active Epstein-Barr virus, virus or virus Malignant disease, other than that being treated in this study

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Dosing Schedule A

    Patients were treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month

    Drug: MIW815 · Biological: PDR001

  • Experimental
    Dosing Schedule B

    Patients were treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month

    Drug: MIW815 · Biological: PDR001

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs)

    A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment with the combination of MIW815 (ADU-S100) and PDR001

    Time frame: 24 months

Secondary outcomes

  1. AUC inf

    The area under the concentration-time curve extrapolated to infinity (mass\*time/volume)

    Time frame: 36 months

  2. AUC last

    The area under the concentration (AUC) -time curve calculated to the last quantifiable concentration point (mass\* time/volume)

    Time frame: 36 months

  3. AUC tau

    Area under the concentration-time curve calculated to the end of the dosing interval (tau) (mass\* time/volume)

    Time frame: 36 months

  4. Tmax

    The time to reach the maximum observed concentration (time)

    Time frame: 36 months

  5. Cmax

    The maximum observed concentration (Cmax) following dose administration (mass/volume)

    Time frame: 36 months

  6. Lambda_z

    Terminal elimination rate constant (1/time)

    Time frame: 36 months

  7. CL/F

    Apparent systemic clearance of drug from the plasma (volume x time -1)

    Time frame: 36 months

  8. T1/2

    Elimination half-life, determined as 0.693/Lambda_z (time)

    Time frame: 36 months

  9. Vz/F

    Apparent volume of distribution during the terminal elimination phase (volume)

    Time frame: 36 months

  10. Best overall response (BOR)

    Best overall response will be summarized

    Time frame: 36 months

  11. Overall response rate (ORR)

    Overall response rate will be summarized with accompanying 90% exact binomial confidence interval (CI).

    Time frame: 36 months

  12. Progression free survival (PFS)

    The survival function will be estimated using the Kaplan-Meier product limit method. Median duration, with a two-sided Brookmeyer-Crowley 90% confidence interval and Kaplan-Meier estimates of survival proportions will be provided at specified time points.

    Time frame: 36 months

  13. Disease control rate (DCR)

    The disease control rate is calculated as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease

    Time frame: 36 months

  14. Time to response (TTR)

    Time To Response is the time from first dose to first documented response (CR or PR). TTR will be summarized

    Time frame: 36 months

  15. Duration of Response (DOR)

    Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due to study indication. Estimates will use Kaplan-Meier method

    Time frame: 36 months

  16. Tumor infiltrating lymphocytes (TIL)

    Induction of TILs in the injected lesion (local PD effect) and in a non-injected lesion (distal PD effect) will be assessed using paired tumor samples at screening and on-treatment.

    Time frame: 36 months

07

Study locations

12 sites
  • The Angeles Clinic and Research Institute
    Los Angeles, California 90025, United States
  • Novartis Investigative Site
    Chicago, Illinois 60637, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98105, United States
  • Novartis Investigative Site
    North Sydney, New South Wales 2060, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Chuo ku, Tokyo 104 0045, Japan
  • Novartis Investigative Site
    Amsterdam, 1066 CX, Netherlands
  • Novartis Investigative Site
    Hospitalet de LLobregat, Catalunya 08907, Spain
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
08

References and documents

Publications

  • Gogoi H, Mansouri S, Jin L. The Age of Cyclic Dinucleotide Vaccine Adjuvants. Vaccines (Basel). 2020 Aug 13;8(3):453. doi: 10.3390/vaccines8030453. PubMed 32823563 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Dec 2020, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2017
First posted
Jun 1, 2017
StartActual
Sep 8, 2017
Primary completionActual
Dec 18, 2020
CompletionActual
Dec 18, 2020
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03172936
Responsible party
Sponsor
First posted
Jun 1, 2017
Start date
Sep 8, 2017
Primary completion
Dec 18, 2020
Completion
Dec 18, 2020
Last update
May 3, 2022

Study contacts

Nancy Lewis, MD
study director · Novartis

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ADU-S100 · Spartalizumab

Start the discussion